Pill-in-the-Pocket Flecainide: How Much Wall Thickness Is Too Much?
A single patient whose paroxysmal AF is textbook for pill-in-pocket therapy — except for one echocardiographic finding that isn't officially disqualifying, and isn't officially reassuring either.
J.M., a 46-year-old man, has directed his high school's marching band for eighteen years, which means every autumn Saturday morning finds him on a football field for three hours conducting brass sections through pregame warmups — not incidental, since his first AF episode happened mid-rehearsal two years ago, and he's had four more since, always on his feet, always during a stretch of sustained activity. Each episode runs six to eighteen hours, converts on its own, and leaves him wrung out for the rest of the day; none has sent him to the hospital, but two forced him to hand the podium to an assistant mid-performance.
His baseline health is otherwise unremarkable for his age, though not pristine — he's carried a blood pressure in the 140s over 90s for at least five years, mentioned at annual physicals and never treated beyond “watch it,” and it hasn't been watched particularly closely. A routine echocardiogram ordered after his second AF episode showed normal chamber sizes, an ejection fraction of 60%, and mild concentric left ventricular wall thickening — read as borderline, described in adjectives rather than millimeters, not flagged as clinically significant at the time, and never revisited since. He has declined catheter ablation twice, citing the demands of marching season and a discomfort with the idea of a cardiac procedure. What he wants instead is a rescue strategy he can carry in his pocket for five episodes a year, not a drug he takes every single day for a problem that mostly leaves him alone.
Weighing pill-in-pocket flecainide against one echo finding
Nothing about his history argues against pill-in-pocket flecainide. His episodes are exactly the profile the strategy was built for — infrequent, self-terminating, genuinely disruptive to his life — and the exclusion criteria in the literature are specific: ischemic heart disease, an ejection fraction under fifty percent, heart failure, and left ventricular hypertrophy — which for Class IC purposes means a wall thickness of 14mm or more. He has none of those. What his echo showed was mild concentric thickening, explicitly read as borderline by the interpreting cardiologist, and “borderline” in any reasonable reading sits under 14mm.
I'd feel differently if this were his echo six months after starting an antihypertensive that hadn't worked, or if the thickening had progressed on a second study. As a single borderline reading in an untreated hypertensive, it isn't the same finding.
I'm not arguing the exclusion criteria against him — I'm arguing that “mild concentric thickening, read as borderline” is not the same statement as “confirmed not severe.” Class IC proarrhythmia in structural disease is a mortality signal, not just an efficacy question, and the reason that matters here is that his hypertension has never actually been treated. Untreated hypertension is the most common driver of exactly this kind of wall thickening, and it can still be progressing under a reading that predates his last three episodes.
I'm not asking him to have an ablation or take a daily antiarrhythmic. I'm asking for a current echo with a wall thickness reported in millimeters against that 14mm line — not a qualitative adjective — plus an exercise treadmill test, which is a low-burden ask before committing him to a drug class where “we were wrong about how mild it was” isn't a recoverable mistake.
There's a version of this where both of you are arguing about the wrong variable. He's had a blood pressure in the 140s for five years that nobody has treated, and that's the more immediate problem regardless of what we decide about flecainide — it's very plausibly what produced the thickening in the first place, and leaving it untreated means whatever we decide today keeps getting re-litigated at every future echo. Starting an antihypertensive now doesn't cost him anything he isn't already losing.
Agreed: start lisinopril now for his long-untreated hypertension, obtain a current echocardiogram with wall thickness measured in millimeters against the 14mm Class IC threshold, and add an exercise treadmill test before any flecainide decision is finalized. Metoprolol tartrate continues as his as-needed rate control in the meantime.
Pill-in-pocket flecainide proceeds as planned, with the first dose given in a monitored setting and taken at least 30 minutes after his beta-blocker, never on its own.
Class IC therapy is off the table, and the conversation shifts to sotalol or ablation instead.
The electrophysiologist and the pharmacologist never fully reconciled their reading of the same echo report — one calls it reassuring, the other calls it inconclusive — and rather than settle that disagreement by argument, they settled it by ordering better data.